Clearline Capital LP Sells 416,029 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Clearline Capital LP cut its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 18.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,810,483 shares of the biotechnology company's stock after selling 416,029 shares during the period. Clearline Capital LP owned 1.19% of Heron Therapeutics worth $2,770,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Congress Park Capital LLC increased its position in Heron Therapeutics by 24.1% during the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after acquiring an additional 477,417 shares during the period. Quinn Opportunity Partners LLC bought a new position in Heron Therapeutics during the 4th quarter worth $581,000. JPMorgan Chase & Co. raised its holdings in Heron Therapeutics by 172.2% in the 4th quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock valued at $861,000 after acquiring an additional 356,053 shares in the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of Heron Therapeutics during the 4th quarter valued at $459,000. Finally, CM Management LLC lifted its position in shares of Heron Therapeutics by 40.0% during the 4th quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock valued at $1,071,000 after acquiring an additional 200,000 shares during the period. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Price Performance

Shares of Heron Therapeutics stock traded down $0.18 during trading on Tuesday, reaching $1.87. 1,937,115 shares of the company traded hands, compared to its average volume of 1,760,215. The company has a 50 day moving average price of $2.18 and a 200-day moving average price of $1.82. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93. The firm has a market capitalization of $285.29 million, a PE ratio of -10.39 and a beta of 1.33.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. Equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HRTX. StockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Needham & Company LLC reissued a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.